JP2022519764A5 - - Google Patents
Info
- Publication number
- JP2022519764A5 JP2022519764A5 JP2021547374A JP2021547374A JP2022519764A5 JP 2022519764 A5 JP2022519764 A5 JP 2022519764A5 JP 2021547374 A JP2021547374 A JP 2021547374A JP 2021547374 A JP2021547374 A JP 2021547374A JP 2022519764 A5 JP2022519764 A5 JP 2022519764A5
- Authority
- JP
- Japan
- Prior art keywords
- substituted
- unsubstituted
- pharmaceutically acceptable
- acceptable salt
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962805725P | 2019-02-14 | 2019-02-14 | |
| US62/805,725 | 2019-02-14 | ||
| PCT/US2020/017974 WO2020167984A1 (en) | 2019-02-14 | 2020-02-12 | Bicyclic sulfonamides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022519764A JP2022519764A (ja) | 2022-03-24 |
| JP2022519764A5 true JP2022519764A5 (enExample) | 2023-02-21 |
Family
ID=72045615
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021547374A Pending JP2022519764A (ja) | 2019-02-14 | 2020-02-12 | 二環式スルホンアミド |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11033556B2 (enExample) |
| EP (1) | EP3924357A4 (enExample) |
| JP (1) | JP2022519764A (enExample) |
| KR (1) | KR20210126636A (enExample) |
| CN (1) | CN113423712A (enExample) |
| AU (1) | AU2020221839B2 (enExample) |
| BR (1) | BR112021015864A2 (enExample) |
| CA (1) | CA3128061A1 (enExample) |
| IL (1) | IL284940A (enExample) |
| MX (1) | MX2021009717A (enExample) |
| SG (1) | SG11202108835SA (enExample) |
| TW (1) | TW202045516A (enExample) |
| WO (1) | WO2020167984A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3976056A2 (en) | 2019-05-31 | 2022-04-06 | Aligos Therapeutics, Inc. | Modified gapmer oligonucleotides and methods of use |
| CN115160344A (zh) * | 2021-04-06 | 2022-10-11 | 上海长森药业有限公司 | 通过口服给药抑制CD4+Treg细胞的药物和方法 |
| CN118201942A (zh) | 2021-09-08 | 2024-06-14 | 阿利戈斯治疗公司 | 经修饰的短干扰核酸(siNA)分子和其用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10875876B2 (en) * | 2015-07-02 | 2020-12-29 | Janssen Sciences Ireland Uc | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B |
| CN108264520B (zh) * | 2017-01-03 | 2021-12-07 | 上海长森药业有限公司 | 用于治疗乙型肝炎的化合物及其用途 |
| CN109251212A (zh) * | 2017-07-14 | 2019-01-22 | 上海长森药业有限公司 | 内环硫醚酰胺-芳基酰胺类化合物及其治疗乙型肝炎的用途 |
-
2020
- 2020-02-12 MX MX2021009717A patent/MX2021009717A/es unknown
- 2020-02-12 BR BR112021015864-2A patent/BR112021015864A2/pt not_active IP Right Cessation
- 2020-02-12 US US16/789,298 patent/US11033556B2/en active Active
- 2020-02-12 KR KR1020217028108A patent/KR20210126636A/ko not_active Ceased
- 2020-02-12 SG SG11202108835SA patent/SG11202108835SA/en unknown
- 2020-02-12 WO PCT/US2020/017974 patent/WO2020167984A1/en not_active Ceased
- 2020-02-12 EP EP20755416.3A patent/EP3924357A4/en not_active Withdrawn
- 2020-02-12 AU AU2020221839A patent/AU2020221839B2/en not_active Ceased
- 2020-02-12 CN CN202080013579.9A patent/CN113423712A/zh active Pending
- 2020-02-12 JP JP2021547374A patent/JP2022519764A/ja active Pending
- 2020-02-12 CA CA3128061A patent/CA3128061A1/en active Pending
- 2020-02-14 TW TW109104831A patent/TW202045516A/zh unknown
-
2021
- 2021-07-19 IL IL284940A patent/IL284940A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017512789A5 (enExample) | ||
| ES2831333T3 (es) | Moduladores de la proteína nuclear de la hepatitis B | |
| JP2021534124A5 (enExample) | ||
| KR970705393A (ko) | 암 치료를 위한 화합물 및 방법(compounds and methods for the treatment of cancer) | |
| JP2016534148A5 (enExample) | ||
| JP2011509309A5 (enExample) | ||
| JP2020521740A5 (enExample) | ||
| JP2022505597A5 (enExample) | ||
| JP2020515610A5 (enExample) | ||
| JP2015526448A5 (enExample) | ||
| JP2019500387A5 (enExample) | ||
| JP2017518959A5 (enExample) | ||
| JP2017528498A5 (enExample) | ||
| JP2022505841A5 (enExample) | ||
| JP2022522312A5 (enExample) | ||
| JP2008535903A5 (enExample) | ||
| JP2016527217A5 (enExample) | ||
| JP2020507589A5 (enExample) | ||
| JP2006507355A5 (enExample) | ||
| JP7648528B2 (ja) | モノマーおよびマルチマー抗ｈｂｖ薬 | |
| HK1253337B (en) | Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| JP2023513797A5 (enExample) | ||
| JP2022505989A5 (enExample) | ||
| JP2022529466A5 (enExample) | ||
| JP2008535803A5 (enExample) |